TOP TEN perturbations for 39039_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39039_s_at
Selected probe(set): 222435_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39039_s_at (222435_s_at) across 6431 perturbations tested by GENEVESTIGATOR:
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-3.7904224Number of Samples:4 / 8
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):-3.3070164Number of Samples:4 / 4
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (CpG A; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-3.1273632Number of Samples:2 / 2
| Experimental | zalypsis study 2 |
| OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated OPM1 cell sample |
| OPM1 multiple myeloma cells untreated. |
Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample
Relative Expression (log2-ratio):-3.1000824Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal plasmocytoid dendritic cell sample |
| Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-3.028821Number of Samples:7 / 8
| Experimental | dendritic cell study 6 (gardiquimod) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (ductal and lobular carcinoma; primary)
Relative Expression (log2-ratio):2.826376Number of Samples:2 / 4
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (ductal and lobular carcinoma; primary) |
| Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma. |
male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):-2.6664238Number of Samples:5 / 8
| Experimental | male infertility study 1 (juvenile; Ad+) |
| Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
male infertility study 1 (mJS2) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):-2.6458826Number of Samples:7 / 8
| Experimental | male infertility study 1 (mJS2) |
| Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained almost exclusively Sertoli cells. Tissue samples were classified based on modified Johnsen score (mJS) as mJS2. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
male infertility study 1 (mJS3) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):-2.629695Number of Samples:3 / 8
| Experimental | male infertility study 1 (mJS3) |
| Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained Sertoli cells but rarely spermatogonia. Tissue samples were classified based on modified Johnsen score (mJS) as mJS3. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)
Relative Expression (log2-ratio):2.5976152Number of Samples:6 / 6
| Experimental | memory B cell study 1 (CD27high) |
| CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours. | |
| Control | memory B cell study 1 (undivided) |
| CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours. |